Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company
pioneering messenger RNA (mRNA) therapeutics and vaccines to create a
new generation of transformative medicines for patients, today announced
that it will host its annual Science Day for analysts and investors on
Tuesday, May 7, 2019 at 8:00 a.m. ET in Cambridge, MA. Moderna also
announced that it will report its first quarter 2019 financial results
before the market opens on Wednesday, May 8, 2019 and, subsequently,
host a conference call to discuss these results and provide a corporate
update.

Science Day:

Moderna’s Science Day will feature presentations from Stephen Hoge M.D.,
president and Melissa Moore Ph.D., chief scientific officer of Moderna’s
mRNA Research Platform with a focus on the Company’s newest advances
from its commitment to basic and applied sciences. Moderna will also
host a tour of the Norwood manufacturing facility in the afternoon.

First Quarter 2019 Financial Results:

Moderna’s first quarter 2019 financial results and corporate update
conference call will begin at 8:00 a.m. ET on May 8, 2019. To access the
live conference call, please dial 866-922-5184 (domestic) or
409-937-8950 (international), and refer to conference ID 8273939.

Both events will be webcast live under “Events & Presentations” in the
Investors section of the Moderna website at https://investors.modernatx.com/.
The archived webcasts will be available on Moderna’s website
approximately two hours after each event and will be available for 30
days following the events.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class
of transformative medicines for patients. mRNA medicines are designed to
direct the body’s cells to produce intracellular, membrane or secreted
proteins that have a therapeutic or preventive benefit with the
potential to address a broad spectrum of diseases. Moderna’s platform
builds on continuous advances in basic and applied mRNA science,
delivery technology and manufacturing, providing the Company the
capability to pursue in parallel a robust pipeline of new development
candidates. Moderna is developing therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases and cardiovascular
diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic
alliances for development programs with AstraZeneca, Plc. and Merck,
Inc., as well as the Defense Advanced Research Projects Agency (DARPA),
an agency of the U.S. Department of Defense and the Biomedical Advanced
Research and Development Authority (BARDA), a division of the Office of
the Assistant Secretary for Preparedness and Response (ASPR) within
the U.S. Department of Health and Human Services (HHS). Moderna has been
ranked in the top ten of Science’s list of top biopharma
industry employers for the past four years. To learn more, visit www.modernatx.com.

Contacts

Moderna Contacts:
Investors:
Lavina Talukdar
Head,
Investor Relations
617-209-5834
[email protected]

Media:
Jason Glashow
Head, Corporate Communications
617-674-5648
[email protected]